Omeros Co. (NASDAQ:OMER) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Omeros Co. (NASDAQ:OMER) have earned a consensus recommendation of “Moderate Buy” from the five research firms that are currently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $22.50.

A number of analysts have weighed in on the stock. Cantor Fitzgerald restated a “neutral” rating on shares of Omeros in a research report on Thursday, November 14th. Needham & Company LLC restated a “hold” rating on shares of Omeros in a research report on Friday, January 17th. RODMAN&RENSHAW upgraded Omeros to a “strong-buy” rating in a research report on Thursday, November 14th. Rodman & Renshaw initiated coverage on Omeros in a report on Thursday, November 14th. They set a “buy” rating and a $9.00 price target on the stock. Finally, D. Boral Capital reiterated a “buy” rating and issued a $36.00 price objective on shares of Omeros in a report on Thursday, January 16th.

Institutional Investors Weigh In On Omeros

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Barclays PLC increased its position in Omeros by 121.3% during the 3rd quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company’s stock valued at $376,000 after purchasing an additional 51,873 shares during the period. State Street Corp increased its position in shares of Omeros by 0.3% during the third quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock worth $4,867,000 after buying an additional 3,839 shares during the period. HighTower Advisors LLC raised its stake in Omeros by 7.2% during the third quarter. HighTower Advisors LLC now owns 59,339 shares of the biopharmaceutical company’s stock worth $235,000 after buying an additional 4,000 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Omeros by 0.5% in the third quarter. Geode Capital Management LLC now owns 1,339,251 shares of the biopharmaceutical company’s stock valued at $5,318,000 after buying an additional 6,839 shares during the period. Finally, MML Investors Services LLC grew its holdings in Omeros by 19.2% during the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock worth $74,000 after acquiring an additional 3,000 shares during the period. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros Trading Down 1.9 %

OMER stock opened at $9.15 on Friday. The stock has a market capitalization of $530.24 million, a P/E ratio of -3.96 and a beta of 2.01. The firm has a 50-day moving average price of $9.45 and a 200-day moving average price of $6.07. Omeros has a 12 month low of $2.61 and a 12 month high of $13.60.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.